Edition:
United States

Taro Pharmaceutical Industries Ltd (TARO.N)

TARO.N on New York Stock Exchange

108.31USD
20 Oct 2017
Change (% chg)

$0.42 (+0.39%)
Prev Close
$107.89
Open
$108.00
Day's High
$108.70
Day's Low
$107.12
Volume
15,383
Avg. Vol
18,480
52-wk High
$124.31
52-wk Low
$92.28

Latest Key Developments (Source: Significant Developments)

Taro reports qtrly EPS $2.05
Monday, 22 May 2017 06:41pm EDT 

May 22 (Reuters) - Taro Pharmaceutical Industries Ltd :Taro provides results for year ended March 31, 2017.Q4 sales $196.4 million.Qtrly earnings per share $2.05.  Full Article

Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis
Tuesday, 25 Apr 2017 07:30am EDT 

April 25 (Reuters) - Crescita Therapeutics Inc :Crescita Therapeutics announces agreement with Taro Pharmaceuticals for Pliaglis.Crescita Therapeutics - entered development and commercialization license agreement with Taro Pharmaceuticals, unit of Taro Pharmaceutical Industries.Crescita Therapeutics - under terms of agreement, Crescita has granted Taro exclusive license to rights to sell and distribute Pliaglis in U.S. market.Crescita Therapeutics Inc - in consideration of rights granted under agreement taro will make an upfront, non-dilutive payment of US$2.0 million to Crescita.Crescita Therapeutics Inc - under deal Taro will also make up to US$5.75 million in non-dilutive development and sales milestone payments to Crescita.Crescita Therapeutics Inc - in addition, Crescita and Taro have entered into a fee-for-service development agreement.Crescita Therapeutics Inc - Crescita retains all rights to Pliaglis in Canada and Mexico.Crescita Therapeutics Inc - fee-for-service development with Taro wherein co to provide services related to development of Pliaglis and enhanced formulation.Crescita Therapeutics Inc - co to receive fees related to fee-for service development based on services performed.  Full Article

Strongbridge Biopharma announces acquisition of U.S. rights to Keveyis from Taro
Friday, 23 Dec 2016 08:01am EST 

Strongbridge Biopharma Plc : Strongbridge Biopharma Plc says taro is also eligible to receive additional future payments upon achievement of certain sales unit milestones . Strongbridge expects to commercially launch Keveyis in U.S. In April 2017 . Strongbridge Biopharma - under terms of purchase agreement, Strongbridge will provide taro with upfront and deferred payments of $8.5 million in two installments . Strongbridge Biopharma - Taro has agreed to continue to manufacture Keveyis for Strongbridge under an exclusive supply agreement at least for period of Keveyis orphan exclusivity .Strongbridge Biopharma Plc announces acquisition of U.S. Rights to Keveyis® from Taro.  Full Article

Taro Pharmaceutical Industries names Uday Baldota CEO
Tuesday, 22 Nov 2016 08:30am EST 

Taro Pharmaceutical Industries Ltd : Taro Pharmaceutical Industries Ltd- Uday Baldota as chief executive officer . Says Uday Baldota appointed CEO .Taro announces appointment of new ceo and new board member nominations.  Full Article

Taro appoints new chief financial officer
Monday, 3 Oct 2016 05:07pm EDT 

Taro Pharmaceutical Industries Ltd : Taro appoints new chief financial officer .Appointment of Mariano Balaguer as vice president, CFO and chief accounting officer, effective today.  Full Article

Taro posts qtrly earnings per share $2.59
Wednesday, 10 Aug 2016 05:12pm EDT 

Taro Pharmaceutical Industries Ltd : Taro provides results for quarter ended June 2016 . Quarterly sales $233.8 million .Quarterly earnings per share $2.59.  Full Article

Taro Pharma CEO Kal Sundaram to return to Sun Pharma headquarters by the end of 2016
Wednesday, 6 Jul 2016 05:02pm EDT 

Taro Pharmaceutical Industries Ltd : Taro ceo Kal Sundaram to return to Sun Pharma headquarters by the end of 2016 . Sundaram informed taro's board of his intention to step down as ceo by end of current calendar year .Board will conduct a formal process to appoint a ceo for taro.  Full Article

Amarin appoints Michael Kalb chief financial officer
Thursday, 30 Jun 2016 07:30am EDT 

Amarin Corporation Plc : Amarin appoints Michael Kalb chief financial officer .Kalb joins Amarin from Taro Pharmaceutical Industries Ltd.  Full Article

Taro pharmaceutical industries Q4 shr $2.68
Thursday, 26 May 2016 06:33pm EDT 

Taro Pharmaceutical Industries Ltd : Qtrly net sales of $265.1 million, increased $20.9 million, or 8.6%, on relatively flat volumes . Taro provides results for year ended march 31, 2016 . Q4 earnings per share $2.68 .Q4 sales rose 8.6 percent to $265.1 million.  Full Article

BRIEF-Taro announces joining of CEO

* Taro Pharmaceutical Industries Ltd - ‍ Uday Baldota has joined company as its chief executive officer ("CEO") effective August 28, 2017​